1
|
Masamrekh RA, Kuzikov AV, Filippova TA, Sherbakov KA, Veselovsky AV, Shumyantseva VV. Interaction of Abiraterone and Its Pharmacologically Active Metabolite D4A with Cytochrome P450 2C9 (CYP2C9). BIOCHEMISTRY (MOSCOW), SUPPLEMENT SERIES B: BIOMEDICAL CHEMISTRY 2022. [DOI: 10.1134/s1990750822040059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
2
|
Masamrekh RA, Kuzikov AV, Filippova TA, Sherbakov KA, Veselovsky AV, Shumyantseva VV. [The interactions of abiraterone and its pharmacologically active metabolite D4A with cytochrome P450 2C9 (CYP2C9)]. BIOMEDITSINSKAIA KHIMIIA 2022; 68:201-211. [PMID: 35717584 DOI: 10.18097/pbmc20226803201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Interactions of cytochrome P450 2C9 (CYP2C9) were studied with the antitumor drug abiraterone and its pharmacologically active metabolite D4A, promising as an agent for prostate cancer treatment. It was shown by absorption spectroscopy, that both investigated compounds induced spectral changes of CYP2C9, indicating interactions of the pyridine nitrogen atom with the heme iron ion of the active site of the enzyme, but interactions of the ligands with the enzyme could be mediated by a water molecule bound to the heme iron ion. Based on the spectral changes, the values of dissociation constants (KS) for complexes of abiraterone and D4A with CYP2C9 were calculated as 1.73±0.14 μM and 3.95±0.16 μM. Both compounds inhibited O-demethylase activity of CYP2C9 towards its substrate. At 100 μM concentration of naproxen the concentrations of abiraterone, D4A and sulfaphenazole inhibiting CYP2C9 activity by 50% (IC50) were determined as 13.9 μM, 40 μM and 41 μM, respectively. The obtained results can be used for prognosis of drug-drug interactions at CYP2C9 level during administration of abiraterone or D4A as an antitumor agent for prostate cancer treatment in complex pharmacotherapy.
Collapse
Affiliation(s)
- R A Masamrekh
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| | - A V Kuzikov
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| | - T A Filippova
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| | | | - A V Veselovsky
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| | - V V Shumyantseva
- Institute of Biomedical Chemistry, Moscow, Russia; Pirogov Russian National Research Medical University, Moscow, Russia
| |
Collapse
|
3
|
Masamrekh RA, Filippova TA, Haurychenka YI, Sherbakov KA, Veselovsky AV, Shumyantseva VV, Kuzikov AV. The interactions of a number of steroid-metabolizing cytochromes P450 with abiraterone D4A metabolite: spectral analysis and molecular docking. Steroids 2020; 162:108693. [PMID: 32645328 DOI: 10.1016/j.steroids.2020.108693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Revised: 06/24/2020] [Accepted: 06/29/2020] [Indexed: 10/23/2022]
Abstract
The interactions of pharmacologically active 3-keto-Δ4-metabolite of anticancer drug abiraterone (D4A) with steroid-metabolizing cytochromes P450 (CYP51A1, CYP11A1, CYP19A1) was studied by absorption spectroscopy and molecular docking. Both abiraterone and D4A induce type I spectral changes of CYP51A1, one of the enzymes of cholesterol biosynthesis. We have revealed that D4A did not induce spectral changes of CYP11A1, the key enzyme of pregnenolone biosynthesis, unlike abiraterone (type II ligand of CYP11A1). On the contrary, D4A interacts with the active site of CYP19A1, the key enzyme of estrogen biosynthesis, inducing type II spectral changes, while abiraterone does not. Spectral analysis allowed us to calculate spectral dissociation constant (KS) for each complex of cytochrome P450 with respective ligands. The data were supported by molecular docking. The obtained results broaden understanding of interactions of D4A with some of the key steroid-metabolizing cytochromes P450 and allow one to predict possible disproportions of steroid metabolism.
Collapse
Affiliation(s)
- Rami A Masamrekh
- Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, Moscow 117997, Russia; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia
| | - Tatiana A Filippova
- Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, Moscow 117997, Russia; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia
| | - Yaraslau I Haurychenka
- Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, Moscow 117997, Russia
| | - Kirill A Sherbakov
- Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia
| | - Alexander V Veselovsky
- Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia
| | - Victoria V Shumyantseva
- Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, Moscow 117997, Russia; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia
| | - Alexey V Kuzikov
- Pirogov Russian National Research Medical University, Ostrovitianov Street, 1, Moscow 117997, Russia; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow 119121, Russia.
| |
Collapse
|